Journal article icon

Journal article

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine

Abstract:
Background:
A proportion of people with treatment-resistant schizophrenia fail to show improvement on clozapine treatment. Knowledge of the sociodemographic and clinical factors predicting clozapine response may be useful in developing personalised approaches to treatment.

Methods:
This retrospective cohort study used data from the electronic health records of the South London and Maudsley (SLaM) hospital between 2007 and 2011. Using the Least Absolute Shrinkage and Selection Operator (LASSO) regression statistical learning approach, we examined 35 sociodemographic and clinical factors’ predictive ability of response to clozapine at 3 months of treatment. Response was assessed by the level of change in the severity of the symptoms using the Clinical Global Impression (CGI) scale.

Results:
We identified 242 service-users with a treatment-resistant psychotic disorder who had their first trial of clozapine and continued the treatment for at least 3 months. The LASSO regression identified three predictors of response to clozapine: higher severity of illness at baseline, female gender and having a comorbid mood disorder. These factors are estimated to explain 18% of the variance in clozapine response. The model’s optimism-corrected calibration slope was 1.37, suggesting that the model will underfit when applied to new data.

Conclusions:
These findings suggest that women, people with a comorbid mood disorder and those who are most ill at baseline respond better to clozapine. However, the accuracy of the internally validated and recalibrated model was low. Therefore, future research should indicate whether a prediction model developed by including routinely collected data, in combination with biological information, presents adequate predictive ability to be applied in clinical settings.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1177/02698811221078746

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Psychiatry
Role:
Author
ORCID:
0000-0002-8876-4595
More by this author
Role:
Author
ORCID:
0000-0003-3182-905X
More by this author
Role:
Author
ORCID:
0000-0003-2196-4733


More from this funder
Funder identifier:
https://ror.org/03x94j517
Grant:
MR/L017105/1
MR/L011794


Publisher:
SAGE Publications
Journal:
Journal of Psychopharmacology More from this journal
Volume:
36
Issue:
4
Pages:
498-506
Place of publication:
United States
Publication date:
2022-02-25
DOI:
EISSN:
1461-7285
ISSN:
0269-8811
Pmid:
35212240


Language:
English
Keywords:
Pubs id:
1241491
Local pid:
pubs:1241491
Deposit date:
2025-04-05
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP